Efficacy and Safety of Cold Atmospheric Plasma-Assisted Therapy for Herpes Zoster: A Randomized, Parallel, Positive-Controlled, Non-inferiority Multicenter Clinical Trial.

IF 3.5 3区 医学 Q1 DERMATOLOGY
Jingwen Wang, Ke Xue, Jing Gao, Chengda Yuan, Zebin Meng, Linge Li, Lili He, Chenchen Zhang, Xingyu Yang, Jing Wang, Yongmei Lv, Xin Du, Liyun Wang, Chuyu Fu, Na Wang, Yuyan Cheng, Feng Wang, Qing Li, Tingfang Zhang, Yong Cui, Chunjun Yang
{"title":"Efficacy and Safety of Cold Atmospheric Plasma-Assisted Therapy for Herpes Zoster: A Randomized, Parallel, Positive-Controlled, Non-inferiority Multicenter Clinical Trial.","authors":"Jingwen Wang, Ke Xue, Jing Gao, Chengda Yuan, Zebin Meng, Linge Li, Lili He, Chenchen Zhang, Xingyu Yang, Jing Wang, Yongmei Lv, Xin Du, Liyun Wang, Chuyu Fu, Na Wang, Yuyan Cheng, Feng Wang, Qing Li, Tingfang Zhang, Yong Cui, Chunjun Yang","doi":"10.1007/s13555-025-01467-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is growing evidence that cold atmospheric plasma (CAP) can boost skin wound healing and inhibit various viruses. Here, we evaluated the effectiveness and safety of CAP as an adjunct treatment for herpes zoster (HZ). We hypothesized that CAP was similar to or better than the helium-neon (He-Ne) laser in promoting HZ wound and pain recovery.</p><p><strong>Methods: </strong>We recruited 187 patients with acute HZ who received either CAP once per day for at least 2 min per treatment area or He-Ne laser therapy once per day for 20 min per session, in addition to a standard treatment regime. The primary endpoint was the efficacy rate, defined as the percentage of patients in each group whose treated area exhibited drying of blisters in ≥ 50% of the area after the final treatment. Secondary evaluation indicators included treatment duration (in days), onset time of scabbing, scab rate, visual analog scale pain scores, and quality of life scores.</p><p><strong>Results: </strong>Efficacy rates after the last treatment were not significantly different between the CAP and He-Ne laser groups (at 3 ± 1 and 10 ± 2 days after the last treatment, respectively, p > 0.05). Treatment duration, scab formation onset time, and complete scab formation time were shorter in the CAP group than in the He-Ne laser group. No severe adverse events or reactions occurred in the CAP group.</p><p><strong>Conclusion: </strong>CAP is an effective and safe therapeutic option for HZ.</p><p><strong>Trial registration: </strong>This study has been registered at www.chictr.org.cn (ChiCTR2300069993). A graphical abstract is available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01467-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: There is growing evidence that cold atmospheric plasma (CAP) can boost skin wound healing and inhibit various viruses. Here, we evaluated the effectiveness and safety of CAP as an adjunct treatment for herpes zoster (HZ). We hypothesized that CAP was similar to or better than the helium-neon (He-Ne) laser in promoting HZ wound and pain recovery.

Methods: We recruited 187 patients with acute HZ who received either CAP once per day for at least 2 min per treatment area or He-Ne laser therapy once per day for 20 min per session, in addition to a standard treatment regime. The primary endpoint was the efficacy rate, defined as the percentage of patients in each group whose treated area exhibited drying of blisters in ≥ 50% of the area after the final treatment. Secondary evaluation indicators included treatment duration (in days), onset time of scabbing, scab rate, visual analog scale pain scores, and quality of life scores.

Results: Efficacy rates after the last treatment were not significantly different between the CAP and He-Ne laser groups (at 3 ± 1 and 10 ± 2 days after the last treatment, respectively, p > 0.05). Treatment duration, scab formation onset time, and complete scab formation time were shorter in the CAP group than in the He-Ne laser group. No severe adverse events or reactions occurred in the CAP group.

Conclusion: CAP is an effective and safe therapeutic option for HZ.

Trial registration: This study has been registered at www.chictr.org.cn (ChiCTR2300069993). A graphical abstract is available for this article.

低温常压血浆辅助治疗带状疱疹的疗效和安全性:一项随机、平行、阳性对照、非劣效性的多中心临床试验。
越来越多的证据表明,低温大气等离子体(CAP)可以促进皮肤伤口愈合,抑制多种病毒。在这里,我们评估了CAP作为带状疱疹(HZ)辅助治疗的有效性和安全性。我们假设CAP在促进HZ伤口和疼痛恢复方面与氦氖(He-Ne)激光相似或优于氦氖激光。方法:我们招募了187例急性HZ患者,除了标准治疗方案外,他们每天接受一次CAP治疗,每个治疗区域至少2分钟,或者每天接受一次He-Ne激光治疗,每次治疗20分钟。主要终点是有效率,定义为每组治疗区域在最终治疗后水泡干燥≥50%的患者百分比。二级评价指标包括治疗时间(天)、结痂发生时间、结痂率、视觉模拟量表疼痛评分、生活质量评分。结果:CAP组与氦氖激光组末次治疗后的有效率差异无统计学意义(分别为末次治疗后3±1天和10±2天,p < 0.05)。CAP组治疗时间、结痂开始时间、结痂完全形成时间均短于He-Ne激光组。CAP组未发生严重不良事件或反应。结论:CAP是一种安全有效的治疗方案。试验注册:本研究已在www.chictr.org.cn注册(ChiCTR2300069993)。本文的图形摘要是可用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Dermatology and Therapy
Dermatology and Therapy Medicine-Dermatology
CiteScore
6.00
自引率
8.80%
发文量
187
审稿时长
6 weeks
期刊介绍: Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信